8-K: Ekso Bionics Achieves Record Quarterly Sales of $5.0 Million in Q2 2024

Ekso Bionics reported record quarterly sales of $5.0 million in the second quarter of 2024, alongside a gross margin of 53%.

Summary

• Ekso Bionics announced record revenue of $5.0 million for the second quarter of 2024, a 5% increase compared to $4.7 million in the same period last year.
• The company sold 37 EksoHealth devices in the second quarter.
• Gross profit for the quarter was $2.6 million, resulting in a gross margin of 53%, up from 48% in the same quarter of 2023.
• The increase in gross margin was due to higher average selling prices for EksoNR and lower device and service costs.
• Sales and marketing expenses decreased by 21% to $1.8 million, while research and development expenses decreased by 20% to $1.1 million.
• General and administrative expenses decreased by 28% to $2.0 million.
• Net loss for the quarter was $2.4 million, or $0.13 per share, compared to a net loss of $4.2 million, or $0.31 per share, in the second quarter of 2023.
• For the six months ended June 30, 2024, revenue was $8.7 million, slightly down from $8.8 million in the same period of 2023.
• The company sold 66 EksoHealth devices in the first half of 2024.
• Net loss for the first six months was $5.8 million, or $0.33 per share, compared to a net loss of $8.6 million, or $0.64 per share, in the first half of 2023.
• Cash on hand at June 30, 2024, was $5.9 million, down from $8.6 million at the end of 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with record sales and improved margins, but the company is still operating at a loss and has decreasing cash reserves. The pending Medicare claims are a positive sign, but there are still risks associated with reimbursement and market acceptance.

Positives

• The company achieved record quarterly sales, indicating strong market demand.
• Gross margin improved significantly, driven by higher selling prices and lower costs.
• Operating expenses decreased across sales and marketing, research and development, and general and administrative areas.
• Net loss per share improved year-over-year, showing progress towards profitability.
• The company is seeing increased recognition of its EksoNR device as a standard of care.
• The company has Medicare reimbursement mechanisms in place, which is expected to increase demand for Ekso Indego Personal.

Negatives

• Revenue for the first six months of 2024 was slightly lower than the same period in 2023.
• Cash on hand decreased from $8.6 million at the end of 2023 to $5.9 million at June 30, 2024.
• The company is still operating at a net loss, although the loss has decreased year-over-year.

Risks

• The company's ability to obtain adequate financing to fund and grow operations is a risk.
• There is a risk that the company may not obtain reimbursement from CMS in a timely manner or at the expected levels.
• The company faces risks related to obtaining insurance coverage beyond CMS.
• The company's ability to achieve broad market acceptance of its products is not guaranteed.
• There are risks associated with the company's sales and marketing efforts and the effectiveness of its partners.
• The company faces risks related to adverse results in future clinical studies and the failure to obtain or maintain patent protection.
• Disruptions in the company's supply chain could negatively impact results.

Future Outlook

The company anticipates increased demand for Ekso Indego Personal in the second half of the year due to Medicare reimbursement mechanisms. They will continue to execute their commercial strategy to drive growth and bring benefits to patients.

Management Comments

• Scott Davis, Chief Executive Officer of Ekso Bionics, stated that they are pleased with their significant progress in the second quarter of 2024, highlighted by record sales and the announcement of CMS national Medicare pricing determination.
• Management is focused on reaching a larger U.S. population of individuals living with a spinal cord injury.
• Management believes key stakeholders recognize the clinical and economic value of their innovative device.

Industry Context

This announcement comes as the exoskeleton industry continues to grow, with increasing adoption in both medical and industrial applications. The company's focus on Medicare reimbursement is a key step in expanding access to their technology for individuals with spinal cord injuries.

Comparison to Industry Standards

• Ekso Bionics' 53% gross margin is a strong result compared to other medical device companies, although specific comparisons would require more detailed financial data from competitors.
• The company's focus on neurorehabilitation and spinal cord injury is a key differentiator in the exoskeleton market, with competitors such as ReWalk Robotics and Cyberdyne also operating in this space.
• The pending Medicare claims for Ekso Indego Personal are a significant development, as successful reimbursement will be a key driver of future growth. This is similar to ReWalk's efforts to secure reimbursement for their devices.

Stakeholder Impact

• Shareholders will be encouraged by the record sales and improved financial metrics, but may be concerned about the decreasing cash reserves.
• Employees may be positively impacted by the company's growth and success.
• Customers, particularly those with spinal cord injuries, will benefit from increased access to the company's technology through Medicare reimbursement.
• Suppliers may see increased demand for their products as the company's sales grow.
• Creditors may be concerned about the company's decreasing cash reserves, but encouraged by the improved financial performance.

Next Steps

• The company will focus on reaching a larger U.S. population of individuals living with a spinal cord injury.
• The company will continue to execute upon its scalable commercial strategy to drive growth.
• Management will host a conference call to discuss the financial results and recent business developments.

Key Dates

Keywords

exoskeleton, medical devices, rehabilitation, spinal cord injury, Medicare, sales, gross margin, financial results, Ekso Bionics, Ekso Indego Personal, EksoNR